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A B S T R A C T
Human pluripotent stem cells (PSCs) are widely used for in vitro disease modeling. One of the challenges in the
field is represented by the ability of converting human PSCs into specific disease-relevant cell types. The nervous
system is composed of a wide variety of neuronal types with selective vulnerability in neurodegenerative dis-
eases. This is particularly relevant for motor neuron diseases, in which different motor neurons populations show
a different susceptibility to degeneration. Here we developed a fast and efficient method to convert human
induced Pluripotent Stem Cells into cranial motor neurons of the branchiomotor and visceral motor subtype.
These populations represent the motor neuron subgroup that is primarily affected by a severe form of amyo-
trophic lateral sclerosis with bulbar onset and worst prognosis. This goal was achieved by stable integration of an
inducible vector, based on the piggyBac transposon, allowing controlled activation of Ngn2, Isl1 and Phox2a
(NIP). The NIP module effectively produced electrophysiologically active cranial motor neurons. Our method
can be easily extended to PSCs carrying disease-associated mutations, thus providing a useful tool to shed light
on the cellular and molecular bases of selective motor neuron vulnerability in pathological conditions.
1. Introduction
Pluripotent stem cells (PSCs) are widely used to model in vitro
neurodegenerative diseases, which usually affect specific subtypes of
neurons. Both human Embryonic Stem Cells (ESCs) and induced
Pluripotent Stem Cells (iPSCs) can be converted into disease relevant
cell types, included neurons, thus providing a cell system to study the
molecular and cellular mechanisms underlying neurodegeneration. The
possibility of deriving patient-specific iPSCs and the recent advent of
genome editing techniques further expand the potential of such sys-
tems, allowing the production of human neurons carrying disease-as-
sociated mutations. PSCs-derived mutant neurons can also provide a
platform to screen for drugs. To fully exploit the potential of PSCs in the
field of neurodegeneration, appropriate protocols for producing pure
populations of specific neuronal subtypes are needed. To this aim, a
significant effort has been put on the development and optimization of
methods to obtain, for instance, cortical (Suzuki and Vanderhaeghen,
2015), dopaminergic (Arenas et al., 2015), hippocampal (Yu et al.,
2014) or motor (Davis-Dusenbery et al., 2014) neurons.
Motor neurons represent the primary cell type affected in a number
of diseases that are collectively referred to as motor neuron diseases,
and include Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular
Atrophy (SMA). The developmental program of motor neurons has been
well decoded (Jessell, 2000). Two main motoneurons subtypes are
present in the central nervous system in human. Spinal motor neurons
are located in the ventral spinal cord and innervate body skeletal
muscles (Price and Briscoe, 2004). Cranial motor neurons reside in the
brainstem (midbrain and hindbrain) and comprise three subsets:
branchiomotor (BM), visceral motor (VM) and somatic motor (SM)
(Guthrie, 2007). BM axons innervate muscles controlling the jaw, facial
expression, pharynx and larynx. VM neurons control salivary and la-
crimal glands, smooth muscle and visceral organs. SM neurons in-
nervate eye (oculomotor, trochlear and abducens) and tongue (hy-
poglossal) muscles. Not all MN subtypes are equally vulnerable in ALS
and SMA. Despite pathogenic proteins are ubiquitously expressed, in
most ALS patients MNs controlling eye movements are generally
spared, MNs innervating pelvic floor muscles are relatively resistant to
degeneration and faster spinal motor units are affected before slower
ones (Nijssen et al., 2017). Differential vulnerability of specific MN
subgroups seems to be due to intrinsic factors, as protective effects were
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observed upon overexpression of oculomotor-enriched factors or re-
duction of spinal MNs-enriched factors (Allodi et al., 2016; Kaplan
et al., 2014).
ALS prognosis depends from the site of onset of the first symptoms
(Wijesekera and Leigh, 2009). Spinal onset ALS is the most frequent,
with symptoms starting in upper and lower limbs, and is usually fatal at
3–5 years post-diagnosis. Conversely, speech and swallowing problems
are noticed first in a more severe form of ALS (bulbar onset), with limb
symptoms arising almost simultaneously. Bulbar onset ALS has the
worst prognosis, with an average survival of 2–3 years. The incidence of
spinal or bulbar onset is not uniformly distributed in patients carrying
different mutations associated to familial ALS (FALS). For instance, the
percentage of bulbar onset is significantly higher in patients with FUS
or TARDBP mutations than that of patients with SOD1 mutations (Yan
et al., 2010).
Taken together, the different susceptibility of specific MNs subtypes
to neurodegeneration and the onset of symptoms in different motor
units seem due to intrinsic factors. Human PSCs represent a promising
system to shed light on these mechanisms, provided that appropriate
protocols are established to convert them into specific MN subtypes. In
this work, we present a method to differentiate human pluripotent stem
cells into cranial MNs. Existing differentiation protocols are generally
designed to generate spinal MNs as they rely on the activity of retinoic
acid (RA), which during embryonic development confer a posterior
character to neural progenitors (Boulting et al., 2011; Amoroso et al.,
2013; Maury et al., 2015). Here we developed an inducible system that
allows fast and efficient generation of cranial MNs with a BM and VM
character, in extremely simplified culture conditions.
2. Material and methods
2.1. Plasmid construction and generation of a stable human iPSC line
The epB-Bsd-TT-NIL and epB-Bsd-TT-NIP plasmids were generated
by inserting the sequences of, respectively, Ngn2-F2A-Isl1-T2A-Lhx3
(NIL) and Ngn2-F2A-Isl1-T2A-Phox2a (NIP) in the enhanced piggyBac
transposable vector epB-Bsd-TT (Rosa et al., 2014). NIL and NIP were
obtained from the iNIL and iNIP constructs described in (Mazzoni et al.,
2013) and cloned between the BamHI and NotI sites of epB-Bsd-TT. The
resulting constructs contain the enhanced piggyBac terminal repeats
flanking a constitutive cassette driving the expression of the Blasticidin
resistance gene fused to the rtTA gene and, in the opposite direction, a
tetracycline-responsive promoter element (TRE) driving the expression
of NIP or NIL. Human iPSCs used in this study belong to the lines WT I
(main figures) and FUS-P525L/P525L (Fig. S1) described in (Lenzi
et al., 2015). iPSCs were co-transfected with 4.5 μg of transposable
vector and 0.5 μg of the piggyBac transposase using the Neon Trans-
fection System (Life Technologies) as previously described (Lenzi et al.,
2015). Selection in 5 μg/ml blasticidin gave rise to stable and inducible
cell lines.
2.2. Cranial and spinal MN differentiation
iPSCs, maintained as previously described (Lenzi et al., 2015), were
dissociated to single cells with Accutase (Thermo Fisher Scientific) and
plated in Nutristem-XF/FF medium (Biological Industries) supple-
mented with 10 μM rock inhibitor (Enzo Life Sciences) on Matrigel (BD
Biosciences) at a density of 100′000 cells/cm2. The day after differ-
entiation was induced by adding 1 μg/ml doxycycline (dox) (Thermo
Fisher Scientific) in Nutristem without bFGF and TGFβ (Biological In-
dustries). Similar results were obtained when DMEM/F12 (Sigma Al-
drich) was used instead of Nutristem without bFGF and TGFβ. Medium
was changed every day. After 48 h of dox induction, medium was
changed to Neurobasal/B27 medium (Neurobasal Medium, Thermo
Fisher Scientific, supplemented with 1X B27, Thermo Fisher Scientific,
1X Glutamax, Thermo Fisher Scientific, 1X NEAA, Thermo Fisher
Scientific, and 0.5X Penicillin/Streptomycin, Sigma Aldrich), con-
taining 5 μMDAPT and 4 μM SU5402 (both from Sigma Aldrich). At day
5, cells were dissociated with Accutase (Thermo Fisher Scientific) and
plated on poly-ornithine/laminin (Sigma Aldrich) or alternatively on
Matrigel (BD Biosciences) coated dishes or 12 well removable chamber
slides or 8 well chamber slides (Ibidi) at the density of 100′000 cells per
cm2. 10 μM rock inhibitor was added for the first 24 h after dissociation.
Neuronal cultures were maintained in neuronal medium (Neurobasal/
B27 medium supplemented with 20 ng/ml BDNF, 10 ng/ml GDNF, both
from PreproTech, and 200 ng/ml L-ascorbic acid, Sigma Aldrich).
2.3. RNA analysis
Total RNA was extracted with the Quick RNA MiniPrep (Zymo
Research) and retrotranscribed with PrimeScript RT reagent Kit (Perfect
Real Time). Targets were analyzed by real-time qRT-PCR with SYBR
Green Power-UP (Thermo Fisher Scientific). The internal control used
was the housekeeping gene ATP5O. Primers sequences are reported in
Table S1.
2.4. Immunostaining
Cells were fixed with 4% PFA for 15min at room temperature.
Immunostaining was performed with anti-Islet-1/2 (1:50, 39.4D5;
DSHB), anti-TUJ1 (1:1000; T2200; Sigma-Aldrich), anti-Phox2b (B-11)
(1:50; sc-376,997; Santa Cruz Biotechnology), anti-CHAT (1:100;
ab144P; Abcam) primary antibodies and anti-mouse Alexa Fluor 488
(1:200, Thermo Fisher Scientific), anti-rabbit Alexa Fluor 594 (1:200,
Immunological Sciences) and anti-goat Alexa Fluor 594 (1:200,
Immunological Sciences) donkey secondary antibodies. Fluorescent
images were acquired at the Olympus iX83 FluoView1200 laser scan-
ning confocal microscope using a UPLSAPO10x2, NA 0,40 air objective.
Standard setting for DAPI, Alexa 488 and Alexa 594 were used. Images
on Fig. 1C were acquired with 2× zoom, 1600×1600 pixel. Images on
Fig. 3 were acquired with 3× zoom, 1024×1024 pixel. Automated
cell counting was performed with the Cell Scoring tool of MetaMorph
software (Molecular Devices).
2.5. Patch-clamp recordings
Whole-cell patch-clamp recordings were used for the functional
characterization of iPSC-derived cranial MNs, plated on Matrigel.
Experiments were performed in a recording chamber continuously
perfused with an external solution containing (in mM): 140 NaCl, 2.8
KCl, CaCl2, 2 MgCl2, 10 HEPES, 10 glucose (pH 7.3 with NaOH;
300mOsm) at room temperature. Borosilicate pipettes were filled with
a solution containing (in mM): 140 K-gluconate, 2 NaCl, 5 BAPTA, 2
MgCl2, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP (pH 7.3 with KOH;
290mOsm). Cells were visualized with a BX51WI microscope
(Olympus). Voltage- and current- clamp recordings were performed
using Axon DigiData 1550 (Molecular Devices). Signals were filtered at
2 KHz, digitized (10 kHz) and collected using Clampex 10 (Molecular
Devices). Whole-cell capacitance (Cm), cell membrane resistance (Rm)
and Resting Membrane Potential (RMP) were measured on line by
Clampex. Cells were clamped at −70mV to measure spontaneous ac-
tivity. An on-line P4 leak subtraction protocol was used for all record-
ings of voltage-activated currents. Voltage steps (50ms duration) from
−100 to +40mV (10mV increment; holding potential −60mV) were
applied to study voltage-activated sodium currents. Voltage-activated
potassium currents were evoked by voltage steps (250ms duration)
from −30 to +50mV (10mV increment, holding potential −40mV).
Firing properties of iPSC-derived cranial MNs were investigated in
current-clamp mode, injecting current pulses (1 s duration) of in-
creasing amplitude (from 20 to 80 pA; 20 pA increment), after imposing
a membrane potential of −60mV to each cell (injection of
−14.6 ± 2.1 pA). Data were analyzed off-line with Clampfit 10 and
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Origin 7 software.
3. Results and discussion
3.1. Generation of stable and inducible iPSC lines
Motor neuron identity in the brainstem is specified by the diffusible
action of FGF8 and retinoic acid (RA), which set the expression of Hox
genes along the rostrocaudal axis. Dorsovental patterning is instead
determined by a gradient of Sonic hedgehog (SHH), diffusing dorsally
from the floor plate and the notochord, which sets two distinct pro-
genitor domains: p3, containing progenitors of BM and VM neurons that
express Nkx2.2 and Nkx2.9; and pMN, containing progenitors of SM
neurons that express Pax6 and Olig2. Postmitotic BM and VM neurons in
the hindbrain are characterized by the expression of Islet-1, Phox2b,
Phox2a and Tbx20, while SM neurons express Hb9, Lhx3 and Lhx4
(Guthrie, 2007). In mouse embryonic stem cells, ectopic expression of
Ngn2, Isl1 and Lhx3 (NIL) induces a spinal MN identity, while Ngn2 and
Isl1 plus Phox2a (NIP) specify cranial MNs (Mazzoni et al., 2013). NIL
ectopic expression has been shown to induce a spinal MN fate in human
PSCs as well (Hester et al., 2011; Goto et al., 2017). However, to the
best of our knowledge, the NIP module has never been used in human.
We have previously shown that MyoD expression from an “en-
hanced” piggyBac vector (epB) can efficiently convert human iPSCs into
skeletal muscle (Lenzi et al., 2016). Replacement of the MyoD coding
sequence with the NIL or NIP module led to the generation of epB-NIL
and epB-NIP vectors, respectively (Fig. 1A). These vectors allow the
coordinated expression of the three factors upon doxycycline exposure.
Human iPSCs were co-transfected with the piggyBac transposase and
either epB-NIL or epB-NIP, generating stable and inducible lines
(hereafter iPSC-NIL and iPSC-NIP). To test the inducible expression
from the constructs, iPSC-NIL and iPSC-NIP cells were treated with
doxycycline for 24 h. As shown in Fig. 1B, we observed a strong in-
duction of the exogenous Ngn2 transcript in both lines. We then assayed
Fig. 1. Generation of iPSC-NIL and iPSC-NIP cells.
(A) Schematic representation of the epB-NIL and epB-NIP constructs. pA: polyadenylation signal; BsdR: blasticidin resistance gene; T2A: self-cleavage peptide; rtTA:
TET transactivator protein gene; Pubc: human Ubiquitin C constitutive promoter; TRE: TET responsive element; Dox: doxycycline. Black triangles represent terminal
repeats of the transposon. (B) iPSC-NIL and iPSC-NIP cells were collected before (0 h) or after (24 h) 24 h of doxycycline treatment and the expression of Ngn2 was
analyzed by real-time qRT-PCR with primers specific for the exogenous Ngn2. (C) Immunostaining analysis of Isl1/2 protein (green) in iPSC-NIL and iPSC-NIP cells
treated with doxycycline for 24 h. Nuclei were counterstained with DAPI (blue). Scalebar for all panels: 100 μm. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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by immunostaining the production of the transgenic Isl1 protein, which
was detected in>80% of cell nuclei of doxycycline-treated iPSC-NIL
and iPSC-NIP cells (Fig. 1C).
3.2. Fast conversion of iPSC-NIP into cranial MNs
We designed a fast and simple protocol for cranial MN differentia-
tion from iPSC-NIP and, in parallel, iPSC-NIL used as a control for spinal
MN specification. The protocol is outlined in Fig. 2A. NIL and NIP ex-
pression was induced by doxycycline in a medium devoid of bFGF and
TGF-beta agonists. After 48 h, the medium was switched, for additional
3 days, to a neural medium containing the γ-secretase inhibitor DAPT
and the FGF antagonist SU5402. The combined activity of these two
molecules was previously shown to accelerate post-mitotic MNs speci-
fication (Maury et al., 2015; De Santis et al., 2017).
Expression of specific markers was analyzed during the course of
differentiation (Fig. 2B). By day 1, both iPSC-NIL and iPSC-NIP cells
had rapidly downregulated the pluripotency gene NANOG. At day 3 we
observed an increase of the pan-neuronal marker TUBB3 (TUJ1), which
further increased at day 5. Similarly, both cell lines gradually acquired
the expression of the MN gene ISL1. Expression of the choline acetyl-
transferase (CHAT), a characteristic feature of cholinergic neurons and
late MN marker, was slightly induced at day 3 and strongly upregulated
at day 5. Changes in gene expression were paralleled by a change in
morphology during the course of differentiation, with a gradual in-
crease of neuron-like cells over time (Fig. 2C).
We then analyzed the expression of markers of specific MN sub-
types. Notably, HB9 expression was induced at day 3 and further in-
creased at day 5 only in iPSC-NIL, while the cranial MN gene PHOX2B
showed a similar pattern of expression only in iPSC-NIP (Fig. 2D). These
results suggest that during the course of differentiation iPSC-NIL and
iPSC-NIP acquire different and alternative MN identities. We further
confirmed this observation by a comparative analysis of additional
cranial MN markers in the two cell lines. As shown in Fig. 2E, PHOX2B,
TBX20 and RGS4 were highly and significantly enriched in iPSC-NIP-
derived neurons, in the absence of HB9 expression.
Taken together, this pattern of gene expression suggests that Ngn2,
Isl1 and Phox2a combined activity induces a cranial MN fate, with BM
and VM subtypes character, in human iPSCs.
We further confirmed this conclusion by prolonging the culture of
NIP-induced MNs beyond day 5. Cells were dissociated and re-seeded in
the absence of doxycycline. Immunostaining analysis showed that both
iPSC-NIL- and iPSC-NIP-derived neurons expressed the TUJ1 neurofi-
lament, marking mostly post-mitotic neurons (Fig. 3). However, only
iPSC-NIP-derived neurons were positive for the cranial MN marker
PHOX2B. Efficiency of differentiation was assessed by automated cell
counting, resulting in 90% TUJ1-positive cells, of which 95% where
also PHOX2B positive (about 1500 counted cells). Similar results were
obtained with a second human iPSC line, carrying an ALS mutation in
the FUS gene (Lenzi et al., 2015), confirming the robustness of the
differentiation method (Fig. S1).
Fig. 2. MN differentiation.
(A) Schematic representation of the differentiation protocol. Dox: doxycycline. (B) Analysis of the expression of the indicated markers in differentiating iPSC-NIL
(left) or iPSC-NIP (right) cells by real-time qRT-PCR. For each marker the time point with the highest expression has been used as the calibrator sample. Primers used
for ISL1 are specific for the endogenous gene. (C) Brightfield images of differentiating iPSC-NIP at the indicated time points. Scale bar for all panels: 50 μm. (D)
Analysis of the expression of HB9 (left) and PHOX2B (right) in differentiating iPSC-NIL and iPSC-NIP cells by real-time qRT-PCR. Day 0 has been used as the
calibrator sample. (E) Comparative analysis by real-time qRT-PCR of the expression of MN markers after 5 days of differentiation of iPSC-NIL and iPSC-NIP cells.
Histogram bars represent the average of 3 independent experiments and error bars indicate the standard deviation (Student's t-test; paired; two tails;
***= p < 0.001).
Fig. 3. Immunostaining analysis of NIP-induced MNs.
Immunostaining for the cranial MN marker PHOX2B (green) and the pan-neuronal marker TUJ1 (red) in iPSC-NIL and iPSC-NIP cells differentiated as shown in
Fig. 2A, dissociated, re-plated on poly-L-ornithine laminin-coated chambered slides and maintained in neural medium for 24 h. Nuclei are counterstained with DAPI.
Scale bar for all panels: 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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3.3. Functional analysis
We next assessed the degree of maturation achieved by iPSC-NIP-
derived cranial MNs by assessing their functional properties. To
investigate the expression of the passive electrophysiological proper-
ties, patch clamp recordings were performed on iPSC-NIP differentiated
as in Fig. 2A, dissociated, re-plated on Matrigel and maintained for
additional 7–8 days. At this time point, differentiated cells were
Fig. 4. Functional properties of iPSC-NIP-derived cranial MNs.
(A) Left: representative traces of voltage-dependent Na+ currents recorded in an iPSC-NIP-derived cranial MN, in response to the stimulation protocol reported; right:
mean voltage-current relationship of voltage-dependent Na+ currents (n= 33, HP=−60mV). (B) Left: representative recording of voltage-dependent K+ currents
evoked in a iPSC-NIP-derived cranial MN by the voltage steps reported; right: mean voltage-current relationship of voltage-dependent K+ currents (n= 34;
HP=−40mV). (C) Current clamp recording of membrane voltage in response to current injection (20 pA, 1 s) in an iPSC-NIP-derived cranial MN showing a
repetitive firing. (D) Histogram representing the distribution of peak amplitude (pA) of spontaneous glutamatergic events in iPSC-NIP-derived cranial MN culture
recorded at HP=−70mV (n=6). Insert: sample trace of recorded spontaneous synaptic activity.
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consistently CHAT-positive (Fig. S2). Resting membrane potential
(−42.4 ± 1.5mV; n=36) and cell capacitance (20.1 ± 0.9 pF;
n=36) were similar to those previously reported for human iPSC-de-
rived MNs (Devlin et al., 2015), while membrane resistance values were
typical of immature cells (1342 ± 109MΩ; n= 36; Miles et al., 2004).
We then characterized the ability of MNs to generate trains of action
potentials, fundamental to allow muscle contraction. iPSC-NIP-derived
neurons display large inward voltage-dependent Na+ currents
(1044 ± 82 pA at 0mV; n=33; Fig. 4A), activated near −30mV and
peaked at −10–0mV, and voltage-dependent K+ currents
(421 ± 35 pA at +30mV; n= 34; Fig. 4B). Current pulses were able
to induce trains of action potentials in almost all tested cells. The mean
threshold for first action potential generation was −24.2 ± 1.1mV
(n=14; 20 pA of current injection). The minimum current required to
elicit repetitive firing was 29.1 ± 2.9 pA and the firing frequency was
9.8 ± 1.1 Hz (n=14; Fig. 4C). iPSC-NIP induced neurons in culture
display the ability to form functional networks as revealed by the
presence of synaptic events recorded in voltage clamp configuration. As
expected we observed only glutamatergic activity, as using a K-gluco-
nate based intracellular solution no synaptic events were detected when
cells were voltage clamped at 0mV. Conversely at HP=−70mV
spontaneous glutamatergic postsynaptic currents were present in 6 over
14 cells recorded. This spontaneous activity was characterized by a
frequency of 2.0 ± 0.4 Hz (n=6) and a peak amplitude of
−6.3 ± 0.1 pA (n=6; Fig. 4D).
Overall, functional data suggest that iPSC-NIP induced neurons ac-
quire functional properties similar to those previously reported for PSC-
derived MNs (Miles et al., 2004; Devlin et al., 2015).
4. Discussion
One of the major challenges in the use of PSCs for biomedical
purposes is the ability to program their differentiation into cell popu-
lations that are as much as possible enriched in desired cell type.
Differentiation protocols to obtain specific neuronal subtypes are often
costly, time consuming and require cell purification. These issues are
particularly relevant when iPSC-derived neurons are produced for
-omic approaches, requiring high amounts of homogeneous cell popu-
lations. Our method allows to specify human iPSC differentiation into a
disease relevant cell type, cranial VM and BM neurons. So far, cranial
MNs have been derived from human PSCs by differentiation in presence
of a combination of patterning molecules, such as Wnt, FGF, retinoic
acid and Shh, which must be provided at very narrow specific con-
centrations (Maury et al., 2015). Moreover, it has been previously
shown that lentiviral vectors-mediated ectopic expression of Phox2a or
Phox2b increased the fraction of VM neurons obtained when hESCs are
differentiated in presence of FGF8 and Shh (Mong et al., 2014). We
show here that the combined activity of Phox2a, Ngn2 and Isl1 can
quickly convert human iPSCs into cranial MNs with high efficiency and
reproducibility, in absence of patterning molecules and without the
need of viral infection. Stable integration mediated by the epB vector
allowed overcoming the poor transfection efficiency in human iPSCs
(Fig. S3), resulting in about 90% of PHOX2B-positive neurons, con-
sistently, from two different lines. By demonstrating the efficacy of the
NIP module in human, our work extends the previous finding that the
NIL combination could convert human PSCs to spinal MNs (Hester
et al., 2011; Goto et al., 2017). Notably, the degree of maturation
achieved by iPSC-NIP-derived cranial MNs in 11–12 days is similar to
that previously reported for MNs derived from iPSCs by conventional
methods and further matured for 10 weeks in vitro (Devlin et al., 2015).
Moreover, at this time point the vast majority of iPSC-NIP-derived
cranial MNs were CHAT-positive and electrophysiological character-
ization showed their ability to fire a train of action potentials over time
in vitro, reaching a maximum frequency that has been previously re-
ported for MNs derived from human ESCs only after> 31 days
(Takazawa et al., 2012), demonstrating functional maturation.
Several lines of iPSCs carrying MN diseases-associated mutations
have been recently derived (Dimos et al., 2008; Chang et al., 2011;
Bilican et al., 2012; Lenzi et al., 2015) Comparison of cranial versus
spinal MNs derived from those human iPSC lines will allow to shed light
into cell intrinsic determinants that underlie the different susceptibility
to degeneration of specific MN subtypes.
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